Navigation Links
Caraco Pharmaceutical Laboratories, Ltd. Receives Notice Regarding NYSE Amex Continued Listing Standards
Date:7/15/2010

DETROIT, July 15 /PRNewswire-FirstCall/ -- Caraco Pharmaceutical Laboratories, Ltd. (NYSE Amex: CPD) announced that on July 12, 2010, NYSE Amex notified the Company that it was not in compliance with the requirement under its continued listing standards that its audit committee be comprised of three independent members. On July 9, 2010, the Company informed NYSE Amex of its non-compliance with Section 803(B)(2)(a) of NYSE Amex Company Guide following the resignation of Mr. Madhava Reddy as a director of the Company on July 6, 2010, leaving two independent directors on the Company's audit committee. Additionally, the Company notified NYSE Amex that it intends, in conformance with NYSE Amex rules, to add another independent director to the audit committee within 180 days of the resignation.  

Detroit-based Caraco Pharmaceutical Laboratories, Ltd., develops, manufactures, markets and distributes generic pharmaceuticals to the nation's largest wholesalers, distributors, drugstore chains and managed care providers.

Safe Harbor: This news release contains forward-looking statements made pursuant to the safe-harbor provisions of the Private Securities Litigation Reform Act of 1995. Without limitation, the words "believe" or "expect" and similar expressions are intended to identify forward-looking statements. Such statements are based on management's current expectations and are subject to risks and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. These risks and uncertainties are contained in the Corporation's filings with the Securities and Exchange Commission, including Part I, Item 1A of our most recent Form 10-K, and include but are not limited to: information of a preliminary nature that may be subject to adjustment, potentially not obtaining or delay in obtaining FDA approval for new products, governmental restrictions on the sale of certain products, development by competitors of new or superior products or less expensive products or new technology for the production of products, the entry into the market of new competitors, market and customer acceptance and demand for new pharmaceutical products, availability of raw materials, timing and success of product development and launches, dependence on few products generating majority of sales, product liability claims for which the Company may be inadequately insured, material litigation from product recalls, the purported class action lawsuits alleging federal securities laws violations, delays in returning the Company's products to market, including loss of market share, increased reserves against the FDA-seized inventory, and other risks identified in this report and from time to time in our periodic reports and registration statements. These forward-looking statements represent our judgment as of the date of this report. We disclaim, however, any intent or obligation to update our forward-looking statements.


'/>"/>
SOURCE Caraco Pharmaceutical Laboratories, Ltd.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Caraco Pharmaceutical Laboratories, Ltd. Enters Into Consent Decree with FDA Providing Path to Resume Manufacturing Operations
2. Caraco Pharmaceutical Laboratories, Ltd. Closes Asset Purchase Agreement with Forest Laboratories, Inc. to Settle Lexapro(R) (escitalopram oxalate) ANDA Patent Litigation
3. Caraco Pharmaceutical Laboratories, Ltd. Reports Results for the Second Quarter and First Six Months of Fiscal Year 2010
4. Caraco Pharmaceutical Laboratories, Ltd. Markets Generic Acular(R) Opthalmic Solution
5. Caraco Pharmaceutical Laboratories, Ltd. Markets Generic Acular(R) Ophthalmic Solution
6. Caraco Pharmaceutical Laboratories, Ltd. Markets Nicardipine Hydrochloride Injection
7. Caraco Pharmaceutical Laboratories, Ltd. Markets Generic Eloxatin(R)
8. Caraco Pharmaceutical Laboratories, Ltd. Markets Generic Exelon® Capsules
9. Caraco Pharmaceutical Laboratories, Ltd. Markets Generic Optivar®
10. Thomson Scientific Publishes The Ones to Watch - A Quarterly Review of Phase Changes in the Pharmaceutical Pipeline
11. Auxilium Pharmaceuticals, Inc. Receives Clearance to Resume Clinical Trials for XIAFLEX(TM)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/30/2017)... Revenue Prospects by Product Type (Metered Dose Inhalers, Dry ... Respiratory Inhalers - our new study reveals trends, R&D progress, ... If you are involved in this sector you must read this ... revenues streams to 2027, assessing data, trends, opportunities and business prospects ... Discover how ...
(Date:3/29/2017)... NEW YORK , March 29, 2017 ... infection and promote healing of the wound. The industry ... devices and products for the treatment of wounds caused ... that occur due to diseases such as diabetes, skin ... Europe was the largest ...
(Date:3/29/2017)... , March 29, 2017  BioSpecifics Technologies Corp. ... continues to develop collagenase based-therapies with a first ... marketed as XIAFLEX ®  in the U.S. and ... present a corporate overview at the upcoming 16 ... April 5, 2017 at 8:00 a.m. ET in ...
Breaking Medicine Technology:
(Date:3/29/2017)... ... March 29, 2017 , ... ... squash, announced it has enlisted New York City-based sports and entertainment marketing firm ... and procure sponsorship opportunities for the Professional Squash Association (PSA), which includes first-time ...
(Date:3/29/2017)... ... March 30, 2017 , ... Grass pollen is the main cause of hay fever ... stuff. The season for grass pollen runs from May to July each year; with the ... victim to do? HayMax™ allergen barrier balms ( http://www.haymax.us ) provide an effective defense against ...
(Date:3/29/2017)... ... March 30, 2017 , ... Youth Futures International (YFI) premiered ... feedback from high school and college students who have participated in the program every ... and YFI is now accepting applications for enrollment. Visit http://www.ghana.yfiexperience.org to ...
(Date:3/29/2017)... ... March 30, 2017 , ... Sports Brand EXOUS Bodygear ... which retails normally at $29.97; for the remaining days of March, the price will ... reduced to a special price of just $10 (regular retail price $19.97). , The ...
(Date:3/29/2017)... , ... March 29, 2017 , ... ... Hours at a Walgreens store in Mississippi. AngioGenesis Labs, makers of HeartBoost, BrainBest ... in two southeastern states. Ingredients in HeartBoost, an over the counter heart healthy ...
Breaking Medicine News(10 mins):